Charles River, BioMotiv Enter Partnership
News Apr 15, 2016
Through this partnership, Charles River will provide discovery and preclinical development services that will enable BioMotiv to advance discoveries sourced from academic research and non-governmental organizations into novel medicines.
Charles River has committed to invest up to $10 million in BioMotiv. Through the agreement, Charles River will be the preferred drug discovery and preclinical development partner for BioMotiv’s portfolio of technologies and companies. As part of this new relationship, Professor Julie Frearson, Executive Director of Scientific Alliances for Charles River, will be joining BioMotiv’s Advisory Board.
“We look forward to our partnership with BioMotiv, and the opportunity to contribute to its mission of accelerating academic discoveries into novel therapeutics,” said Professor Frearson. “Charles River is uniquely positioned to support all stages of drug discovery and preclinical development, and using our deep industry knowledge and operational excellence, we can accelerate and optimize BioMotiv’s objective to develop innovative therapies.”
Launched in 2012, BioMotiv is the for-profit component of The Harrington Project, a $250 million initiative with an aim of identifying, funding, and rapidly advancing the development of medical discoveries from innovative physician-scientists throughout the United States and United Kingdom.
“Charles River Laboratories’ ability to support the drug research process from discovery through safety testing is unmatched in the industry,” said Baiju R. Shah, Chief Executive Officer of BioMotiv. “Access to Charles River’s extensive portfolio of services offers distinct scientific and operational advantages, which we believe will significantly accelerate the development of breakthrough medicines.”
Researchers have figured out precisely why one drug binds to the serotonin receptor 5-HT2BR and activates it to cause heart problems while very similar drugs do not. They've also discovered why a third drug acts like a 5-HT2BR antagonist - it blocks the receptor's activity - while the very well-known similar hallucinogenic drug LSD does not.READ MORE
Each year in the U.S., at least 23,000 people die from infections caused by antibiotic resistant bacteria. Using computer modeling, researchers are developing the means to prevent some of those deaths. One way bacteria develop resistance is by producing pumps that spit out antibiotics, before they can do any damage. The researchers teased out the details of how one antibiotic pump works.READ MORE